Myeloid-derived suppressor cells: Cancer, autoimmune diseases, and more
Masahiko Shibata, Kotaro Nanno, Daigo Yoshimori, Takahiro Nakajima, Makoto Takada, Takashi Yazawa, Kousaku Mimura, Norio Inoue, Takafumi Watanabe, Kazunoshin Tachibana, Satoshi Muto, Tomoyuki Momma, Yoshiyuki Suzuki, Koji Kono, Shungo Endo, Seiichi Takenoshita
Abstract
// Masahiko Shibata 1 , 2 , 3 , 4 , Kotaro Nanno 2 , 5 , Daigo Yoshimori 2 , 5 , Takahiro Nakajima 2 , 3 , Makoto Takada 4 , 6 , Takashi Yazawa 2 , 3 , 4 , Kousaku Mimura 3 , Norio Inoue 2 , 3 , 4 , Takafumi Watanabe 7 , Kazunoshin Tachibana 8 , Satoshi Muto 9 , Tomoyuki Momma 3 , 4 , Yoshiyuki Suzuki 1 , 4 , 10 , Koji Kono 1 , 3 , 4 , Shungo Endo 11 and Seiichi Takenoshita 12 1 Department of Comprehensive Cancer Treatment and Research at Aizu, Fukushima Medical University, Fukushima, Japan 2 Department of Surgery, Cancer Treatment Center, Aizu Chuo Hospital, Fukushima, Japan 3 Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima, Japan 4 Aizu Oncology Consortium, Fukushima, Japan 5 Department of Surgery, Nippon Medical School, Tokyo, Japan 6 Department of Surgery, Bange Kousei General Hospital, Fukushima, Japan 7 Department of Obstetrics and Gynecology, Fukushima Medical University, Fukushima, Japan 8 Department of Breast Surgery, Fukushima Medical University, Fukushima, Japan 9 Department of Chest Surgery, Fukushima Medical University, Fukushima, Japan 10 Department of Radiation Oncology, Fukushima Medical University, Fukushima, Japan 11 Department of Colorectoanal Surgery, Aizu Medical Center, Fukushima Medical University, Fukushima, Japan 12 Fukushima Medical University, Fukushima, Japan Correspondence to: Masahiko Shibata, email: [email protected] Keywords: MDSC; immunosuppression; Treg; TAM; cancer Received: September 02, 2022     Accepted: October 20, 2022     Published: November 17, 2022 Copyright: © 2022 Shibata et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Although cancer immunotherapy using immune checkpoint inhibitors (ICIs) has been recognized as one of the major treatment modalities for malignant diseases, the clinical outcome is not uniform in all cancer patients. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of immature myeloid cells that possess various strong immunosuppressive activities involving multiple immunocompetent cells that are significantly accumulated in patients who did not respond well to cancer immunotherapies. We reviewed the perspective of MDSCs with emerging evidence in this review. Many studies on MDSCs were performed in malignant diseases. Substantial studies on the participation of MDSCs on non-malignant diseases such as chronic infection and autoimmune diseases, and physiological roles in obesity, aging, pregnancy and neonates have yet to be reported. With the growing understanding of the roles of MDSCs, variable therapeutic strategies and agents targeting MDSCs are being investigated, some of which have been used in clinical trials. More studies are required in order to develop more effective strategies against MDSCs.